MMD Masterclass: Dr. F. Ulloa-Montoya

Mini Symposium: Immunotherapy: harnessing the immune system to treat disease

Date:
25 September 2013 00:00 hrs.
Location:
Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route 289
Title:
Predictive Gene signature in Mage A3 Antigen Secific Cancer Immunotherapy
Speaker(s):

Dr. Fernando Ulloa-Montoya;  GlaxoSmithKline Vaccines, Rixensart, Belgium

Host(s):

Prof. Jolanda de Vries and Prof. Gosse Adema, Department of Tumor Immunology, NCMLS

25-09-2013 00:00:00Europe/AmsterdamPredictive Gene signature in Mage A3 Antigen Secific Cancer Immunotherapy Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route 289Rimlsrimls@radboudumc.nl

Remarks / more information:

UlloaTo detect a pretreatment gene expression signature (GS) predictive of response to MAGE-A3 immunotherapeutic in patients with metastatic melanoma is a major challenge towards personalized therapy. In the patients with melanoma, 84 genes were identified whose expression was associated with clinical benefit.  The same GS was then used to predict the outcome for patients with resected NSCLC treated with MAGE-A3 immunotherapy. Interestingly, GS-positive patients showed a favorable disease-free interval compared with placebo-treated GS-positive patients. The genes identified were mainly immune related, involving interferon gamma pathways and specific chemokines, suggesting that their pretreatment expression influences the tumor's immune microenvironment and the patient's clinical response.



<< back to all events